Guideline Summary: Management of Bacterial Co‑infection in Tuberculosis

1. Simultaneous Treatment of TB and Bacterial Infection

Continue the standard anti‑tuberculosis regimen (rifampicin, isoniazid, pyrazinamide, ethambutol) unchanged when a bacterial co‑infection is diagnosed. [Thorax 1998] 2
Add pathogen‑directed antibiotics based on culture and susceptibility results, without interrupting or modifying the TB regimen unless hepatic toxicity or a major drug interaction occurs. [MMWR Recommendations and Reports 2009] 1
Minimum TB treatment duration is ≥ 6 months for pulmonary disease and ≥ 12 months for central‑nervous‑system (CNS) involvement; shortening or altering the regimen increases the risk of resistance and therapeutic failure. [Thorax 1998] 2

Obtain blood cultures from two separate sites in any TB patient who develops new symptoms suggestive of bacterial infection, especially those with low CD4⁺ counts. [MMWR Recommendations and Reports 2009] 1
Collect sputum for bacterial culture in addition to mycobacterial culture when there is acute respiratory worsening. [MMWR Recommendations and Reports 2009] 1
The most frequent bacterial isolates in TB patients are Streptococcus pneumoniae, Haemophilus spp., and, in advanced HIV (CD4⁺ < 50 cells/µL), Pseudomonas aeruginosa. [MMWR Recommendations and Reports 2009] 1

Community‑acquired bacterial pneumonia – use a β‑lactam (e.g., amoxicillin‑clavulanate or ceftriaxone) or a respiratory fluoroquinolone (levofloxacin or moxifloxacin). [MMWR Recommendations and Reports 2009] 1
Suspected Pseudomonas (e.g., CD4⁺ < 50 cells/µL, bronchiectasis, recent hospitalization) – add anti‑pseudomonal coverage such as piperacillin‑tazobactam or ceftazidime. [MMWR Recommendations and Reports 2009] 1

Rifampicin is a strong inducer of CYP3A4, markedly lowering serum concentrations of protease inhibitors and other CYP3A4‑metabolized drugs. [Clinical Infectious Diseases 2016] 3
In HIV‑positive patients on protease inhibitors, the preferred strategy is to discontinue the protease inhibitor and substitute alternative antiretrovirals during TB therapy. [Praxis Medical Insights 2026] 4
Alternative strategies (when protease‑inhibitor continuation is required) include:

In patients with chronic liver disease, check liver enzymes weekly for the first 2 weeks, then every 2 weeks for the next 2 months. [Thorax 1998] 2
In patients with normal baseline liver function, monitor only if clinical signs of hepatotoxicity appear (fever, malaise, vomiting, jaundice). [Thorax 1998] 2
Discontinue rifampicin, isoniazid, and pyrazinamide if AST/ALT ≥ 5 × the upper limit of normal or if there is a marked bilirubin rise. [Thorax 1998] 2

Assess renal function before initiating aminoglycosides (streptomycin, amikacin) for bacterial coverage or as part of the TB regimen. [Thorax 1998] 2
Adjust doses of ethambutol and aminoglycosides according to creatinine clearance. [Thorax 1998] 2

Perform monthly visual‑acuity testing in all patients receiving ethambutol; stop ethambutol immediately if visual changes are reported. [Thorax 1998] 2

Perform lumbar puncture in every case of miliary TB to detect meningeal involvement, which dictates treatment length (12 months if meningitis present, otherwise 6 months). [Thorax 1998] 2
Use adjunctive corticosteroids (dexamethasone or prednisolone) when tuberculous meningitis is confirmed, irrespective of disease severity. [Praxis Medical Insights 2026] 4

Never interrupt anti‑TB therapy when adding antibiotics for a bacterial infection; accidental TB monotherapy promotes drug resistance. [Thorax 1998] 5
Do not mistake paradoxical reactions (transient radiographic or clinical worsening) for treatment failure or a new bacterial infection; these reactions are common and do not require regimen change. [Praxis Medical Insights 2026] 7
Always treat CNS TB for a full 12 months, regardless of any bacterial co‑infection; a 6‑month regimen is inadequate. [Thorax 1998] 2
Obtain cultures and susceptibility testing before starting therapy for both TB and bacterial pathogens to identify drug resistance early. [MMWR Recommendations and Reports 2009; Clinical Infectious Diseases 2016] [1][3]
Consider multidrug‑resistant TB if there is therapeutic failure or disease recurrence, especially when initial susceptibility testing was not performed. [Clinical Infectious Diseases 2016] 3